Back to Search
Start Over
Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity.
- Source :
-
Annals of laboratory medicine [Ann Lab Med] 2020 Mar; Vol. 40 (2), pp. 101-113. - Publication Year :
- 2020
-
Abstract
- Biological drugs, such as proteins and immunogens, are increasingly used to treat various diseases, including tumors and autoimmune diseases, and biological molecules have almost completely replaced synthetic drugs in rheumatology. Although biological treatments such as anti-tumor necrosis factor (TNF) drugs seem to be quite safe, they cause some undesirable effects, such as the onset of infections due to weakening of the immune system. Given the biological nature of these drugs, they might be recognized as extraneous; this would induce an immune reaction that neutralizes their effectiveness or lead to more serious consequences. Laboratories play a pivotal role in appropriate therapeutic management. The aim of this review was to underline the production of anti-drug antibodies during treatment with biological drugs and highlight the role of laboratories in ensuring appropriate use of these drugs.<br />Competing Interests: None declared.<br /> (© The Korean Society for Laboratory Medicine.)
- Subjects :
- Adalimumab blood
Adalimumab immunology
Adalimumab therapeutic use
Antibodies, Monoclonal blood
Antibodies, Monoclonal immunology
Antibodies, Monoclonal therapeutic use
Arthritis, Rheumatoid drug therapy
Biological Factors immunology
Biological Factors therapeutic use
Biosimilar Pharmaceuticals blood
Biosimilar Pharmaceuticals therapeutic use
Humans
Biological Factors blood
Drug Monitoring
Subjects
Details
- Language :
- English
- ISSN :
- 2234-3814
- Volume :
- 40
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Annals of laboratory medicine
- Publication Type :
- Academic Journal
- Accession number :
- 31650726
- Full Text :
- https://doi.org/10.3343/alm.2020.40.2.101